Table 1 Patient demographics, associated rheumatic disease, HIV-1 duration before initiation of anti-TNF therapy, past therapies and presence of HAART
Patient12345678
Age4834503139445247
GenderMaleMaleFemaleMaleMaleFemaleMaleFemale
EthnicityWhiteWhiteBlackBlackBlackBlackWhiteBlack
HIV statusSeropositiveSeropositiveSeropositiveSeropositiveSeropositiveSeropositiveAIDSSeropositive
Rheumatic diseaseRAASUSpAReAPsARAPsAPsA
HIV duration (months)1224116721453628
Baseline daily prednisone dose15NoneNone10NoneNone“High dose”*None
Previous DMARDsLEF, SSZ, HCQ, MTXSSZSSZMTX, SSZMTX, SSZMTXNoneSSZ, MTX
Taking HAARTYesYesYesNoNoNoYesYes
Baseline CD4 count cells/mm3631634779733750974268446
Baseline viral load copies/mm3<50256425<40022 148<400<50<400
  • TNF, tumour necrosis factor; RA, rheumatoid arthritis; DMARDs, disease modifying antirheumatic drugs; AS, ankylosing spondylitis; USpA, undifferentiated spondyloarthritis; ReA, reactive arthritis; PsA, psoriatic arthritis; LEF, leflunomide; SSZ, sulfasalazine; HCQ, hydroxychloroquine; MTX, methotrexate; HAART, highly active antiretroviral therapy.

  • *Patient was referred from another medical centre where he was taking “high-dose” methylprednisolone over 20 mg/day.